It was reported by united therapeutics that a patient alleges adverse reaction while using opsite iv 3000 in combination of their product, remodulin.Patient reported to her speciality pharmacy that after receiving remodulin (treprostinil) via subcutaneous route for primary pulmornary hypertension, opsite iv 3000, and tegaderm, she began to experience redness and itching at the site.In addition, she reportedly experienced a headache as well.United therapeutics stated no additonal follow-ups will be made regarding this incident.All other parties involved are unknown.
|